Skip to Content
Merck
CN
All Photos(1)

Documents

AB2215

Sigma-Aldrich

Anti-Interferon-β Antibody

serum, Chemicon®

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Anti-IFB, Anti-IFF, Anti-IFN-beta, Anti-IFNB
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

100

antibody form

serum

antibody product type

primary antibodies

clone

polyclonal

species reactivity

mouse

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
neutralization: suitable
western blot: suitable

NCBI accession no.

NM_002176.2

UniProt accession no.

P01574

shipped in

dry ice

target post-translational modification

unmodified

Gene Information

mouse ... Ifnb1(15977)

Specificity

Reacts with mouse Interferon beta (IFNbeta). No reactivity is seen with IFNalpha or gamma

Immunogen

Mouse IgG, whole molecule.

Application

Cytopathic effect inhibition assay: 2 x 10E5 neutralization units per mL of antiserum. One neutralization unit is the amount of antiserum required to neutralize 1 unit of mouse IFN-beta. This material is prepared specifically for effective neutralization of mouse IFN-beta.

Western blot (1:500) The antibody reacts with a 19kDa band coresponding to Mu-IFN-beta. Protocol below:

1. Put protein (approx 50ng) in blocking solution for 30-60 min RT

2. Add Primary antibody (1:500) to blocking solution

3. Agitate membrane for 60 min, RT

4. Wash 3X for 5min each with PBS-Tween

5. Add secondary antibody (1:1000) after diluting in PBS-Tween

6. Gentle agitation for 60min.

7. Wash 3X for 5min each with PBS-Tween

8. Develop with reaction kit of choice

Immunoprecipitation

Immunohistochemistry

ELISA

Optimal working dilutions must be determined by end user.
Detect Interferon-β using this Anti-Interferon-β Antibody validated for use in ELISA, IP, WB, IH, NEUT.
Research Category
Inflammation & Immunology
Research Sub Category
Cytokines & Cytokine Receptors

Packaging

2x10(e4) units

Physical form

Rabbit polyclonal serum in buffer containing 0.3 M NaHCO3 and 200 mM NaCl.

Storage and Stability

Maintain frozen at -20°C or below for retention of full activity, for up to 12 months. When thawing, the contents of the tube should be apportioned in separate tubes so that freezing and thawing is kept to a minimum.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Choon Kit Tang et al.
PloS one, 8(3), e60038-e60038 (2013-04-05)
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been
Anna Niewiadomska-Cimicka et al.
International journal of molecular sciences, 25(8) (2024-04-27)
Polyglutamine (polyQ)-encoding CAG repeat expansions represent a common disease-causing mutation responsible for several dominant spinocerebellar ataxias (SCAs). PolyQ-expanded SCA proteins are toxic for cerebellar neurons, with Purkinje cells (PCs) being the most vulnerable. RNA interference (RNAi) reagents targeting transcripts with
Dwijit GuhaSarkar et al.
Molecular oncology, 11(2), 180-193 (2017-01-18)
The highly invasive property of glioblastoma (GBM) cells and genetic heterogeneity are largely responsible for tumor recurrence after the current standard-of-care treatment and thus a direct cause of death. Previously, we have shown that intracranial interferon-beta (IFN-β) gene therapy by

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service